title: Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.
abstract: Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduction became more pronounced after 8 and 24 weeks' medication. The HDL reduction was confined to the HDL2 subfraction, which was decreased by 15%, 33%, and 58% after 2, 8, and 24 weeks, respectively; there was no significant change in the HDL3 concentration. During treatment, there was a continuous increase in the mean MPA plasma level and a strong inverse correlation between this level and the mean HDL and HDL2 cholesterol concentrations. It was concluded that MPA affects HDL metabolism in a dose-dependent way and in the same direction as other progestins.
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D010386:Pelvic Neoplasms / Q000097:blood / Q000188:drug therapy*; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D003692:Delayed-Action Preparations; D008074:Lipoproteins; D010743:Phospholipids; D014280:Triglycerides; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone